Cargando…
Regional variation in tolvaptan prescribing across England: national data and retrospective evaluation from an expert centre
BACKGROUND: Tolvaptan, a vasopressin V2 receptor antagonist, was approved in 2015 by the UK National Institute for Health and Care Excellence for use in patients with autosomal dominant polycystic kidney disease (ADPKD) and rapid disease progression. Simultaneous guidance was issued by the UK Kidney...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871855/ https://www.ncbi.nlm.nih.gov/pubmed/36726434 http://dx.doi.org/10.1093/ckj/sfac190 |